These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26782001)

  • 1. Understanding the pathogenesis and developing new therapy of systemic sclerosis.
    Sato S
    J Dermatol; 2016 Jan; 43(1):9. PubMed ID: 26782001
    [No Abstract]   [Full Text] [Related]  

  • 2. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.
    Hasegawa M; Hamaguchi Y; Yanaba K; Bouaziz JD; Uchida J; Fujimoto M; Matsushita T; Matsushita Y; Horikawa M; Komura K; Takehara K; Sato S; Tedder TF
    Am J Pathol; 2006 Sep; 169(3):954-66. PubMed ID: 16936269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances on pathogenesis and therapies in systemic sclerosis.
    Yazawa N; Fujimoto M; Tamaki K
    Clin Rev Allergy Immunol; 2007 Oct; 33(1-2):107-12. PubMed ID: 18064573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of antithymocyte globulin in severe cases of progressive systemic sclerosis.
    Tarkowski A; Lindgren I
    Transplant Proc; 1994 Dec; 26(6):3197-9. PubMed ID: 7998113
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
    Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disorders of cellular immunity in systemic scleroderma].
    Sierakowski SJ; Kucharz EJ
    Przegl Lek; 1988; 45(7):592-7. PubMed ID: 3070641
    [No Abstract]   [Full Text] [Related]  

  • 7. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.
    Sakkas LI; Chikanza IC; Platsoucas CD
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):679-85. PubMed ID: 17133253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening.
    Bonroy C; Smith V; Deschepper E; De Keyser F; Devreese K
    J Rheumatol; 2016 Jan; 43(1):247-9. PubMed ID: 26724322
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?
    Simms RW; Lafyatis R
    Rheumatology (Oxford); 2010 Feb; 49(2):201-2. PubMed ID: 20032221
    [No Abstract]   [Full Text] [Related]  

  • 11. [The cutting-edge of medicine; pathogenesis and treatment of systemic sclerosis].
    Sato S
    Nihon Naika Gakkai Zasshi; 2013 May; 102(5):1226-32. PubMed ID: 23847990
    [No Abstract]   [Full Text] [Related]  

  • 12. [Systemic sclerosis (sclerodermia)].
    Vilardell Tarrés M; Fonollosa Pla V
    Med Clin (Barc); 1990 May; 94(19):736-9. PubMed ID: 2201842
    [No Abstract]   [Full Text] [Related]  

  • 13. Unusual case of progressive systemic sclerosis with onset in early childhood and following infectious mononucleosis.
    Urano J; Kohno H; Watanabe T
    Eur J Pediatr; 1981 Jul; 136(3):285-9. PubMed ID: 6973466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in therapy of systemic sclerosis.
    Misra R; Khanna D
    J Assoc Physicians India; 2006 Jun; 54 Suppl():48-51. PubMed ID: 16909717
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.
    Jimenez SA; Derk CT
    Ann Intern Med; 2004 Jan; 140(1):37-50. PubMed ID: 14706971
    [No Abstract]   [Full Text] [Related]  

  • 17. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.
    Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV
    Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cells in systemic sclerosis: emerging evidence from genetics to phenotypes.
    Wu M; Mohan C
    Curr Opin Rheumatol; 2015 Nov; 27(6):537-41. PubMed ID: 26285102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connective tissue diseases: Nucleosomes and systemic sclerosis.
    O'Reilly S; van Laar JM
    Nat Rev Rheumatol; 2016 Mar; 12(3):138-9. PubMed ID: 26841691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.